Luteolin attenuates sepsis‑induced myocardial injury by enhancing autophagy in mice

Sepsis-induced cardiomyopathy (SIc) is a compli- cation of severe sepsis and septic shock characterized by an invertible myocardial depression. This study sought to explore the potential effects and mechanism of luteolin, a flavonoid polyphenolic compound, in lipopolysaccharide (LPS)-induced myocardial injury. Experimental mice were randomly allo- cated into 3 groups (25 mice in each group): The control group (Nc), the LPS group (LPS) and the LPS + luteolin group (LPS + Lut). Before the SIc model was induced, luteolin was dissolved in dMSO and injected intraperitoneally for 10 days into LPS + Lut group mice. Nc group and LPS group mice received an equal volume of dMSO for 10 days. On day 11, the animal model of sepsis-induced cardiac dysfunction was induced by intraperitoneal injection of LPS. A total of 12 h after LPS injection, measurements and comparisons were made among the groups. Luteolin administration improved cardiac function, attenuated the inflammatory response, alleviated mitochondrial injury, decreased oxidative stress, inhibited cardiac apoptosis and enhanced autophagy. In addition, luteolin significantly decreased the phosphorylation of AMP-activated protein kinase (AMPK) in septic heart tissue. The protective effect of luteolin was abolished by 3-methyladenine (an autophagy inhibitor) and dorsomorphin (compound c, an AMPK inhibitor), as evidenced by decreased autophagic activity, destabilized mitochondrial membrane potential and increased apoptosis in LPS-treated cardiomyo- cytes, but was mimicked by 5-aminoimidazole-4-carboxamide Correspondence to: Professor Ming Yuan, department of cardiology, Xijing Hospital, Fourth Military Medical University, 127 changle West Street, Xi'an, Shaanxi 710032, P.R. china E-mail: yuanming@fmmu.edu.cn *contributed equally Key words: sepsis-induced cardiomyopathy, luteolin, AMP- activated protein kinase, autophagy, lipopolysaccharide ribonucleotide ribonucleotide (an AMPK activator), suggesting that luteolin attenuates LPS-induced myocardial injury by increasing autophagy through AMPK activation. Luteolin may be a promising therapeutic agent for treating SIc.